Quantcast

Latest antibodies Stories

Parasite-Blocking Antigen Discovery May Lead To Malaria Vaccine
2014-05-23 08:37:58

[ Watch the Video: Protein May Lead To Malaria Vaccine ] Lawrence LeBlond for redOrbit.com - Your Universe Online Malaria remains a dangerous disease in the developing world, killing more than 627,000 people a year, according to the World Health Organization (WHO). Because most deaths associated with malaria occur in children in Sub-Saharan Africa, finding a vaccine against the deadly virus is all too important. New research, by a team from Rhode Island Hospital (RIH), has uncovered...

2014-05-22 12:27:49

LONDON, May 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Life Science Tools and Reagents: Global Marketshttp://www.reportbuyer.com/pharma_healthcare/medical_devices/life_science_tools_reagents.htmlSTUDY OBJECTIVESNewly developed life sciences tools and reagents promote interdisciplinary research environments that integrate basic biological science with engineering and computational disciplines. BCC Research's goal in conducting this study is to...

2014-05-22 08:29:44

MONROVIA, Calif., May 22, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 8:00 a.m. EDT in New York City, NY. A live audio webcast of the...

2014-05-16 08:25:52

CAMBRIDGE, England, May 16, 2014 /PRNewswire/ -- Series B Financing includes the Wellcome Trust and the Bill & Melinda Gates Foundation Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing US$20 million. The funds will enable Kymab to maximise the potential of its Kymouse(TM)...

2014-05-15 08:32:10

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will present preclinical data comparing activity of XmAb®7195 to omalizumab in reducing IgE, a protein responsible...

2014-05-13 11:31:45

Emory Health Sciences Carbohydrate-binding proteins fill in gaps in immune defenses Our bodies produce a family of proteins that recognize and kill bacteria whose carbohydrate coatings resemble those of our own cells too closely, scientists have discovered. Called galectins, these proteins recognize carbohydrates from a broad range of disease-causing bacteria, and could potentially be deployed as antibiotics to treat certain infections. The results are scheduled for publication in...

2014-05-07 08:32:47

MONROVIA, Calif., May 7, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter financial results after market close on Wednesday, May 14, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial...

2014-05-07 04:22:16

OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that it has obtained the exclusive global rights to certain Xenomouse(R) antibodies generated by Amgen and to ImmunoGen's maytansinoid ADC technology for an undisclosed target. The rights were granted under the existing strategic...

2014-05-02 23:00:27

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides (http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html). (PRWEB) May 03, 2014 Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast...

2014-04-30 08:33:09

Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues SAN DIEGO, April 30, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,709,755, its first patent directed to methods of generating conditionally active antibodies. Conditionally active antibodies are...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related